HALO241220C50000
- 0.10
- 0.000.00%
Halozyme Therapeutics Newsroom
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $77
Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $57
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Cuts Target Price to $57
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $70
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $77
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Analyst Ratings
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $68
JMP Securities Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $73
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $62